Novel application of diammonium glycyrrhizinate

A technology of diammonium glycyrrhizinate and new use, applied in the field of medicine, can solve problems such as high incidence of adverse reactions, no obvious curative effect, and no relevant reports.

Inactive Publication Date: 2020-06-05
GUIZHOU MAQIKA PHARMA
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] At present, for the treatment of the new type of coronavirus pneumonia 2019-nCoV, the initial clinical treatment plan adopted by the hospital is Ai Fu Le combined with oseltamivir and Lianhua Qingwen, and then successively announced arbidol and Lopi for the treatment of HIV Navir and ritonavir are effective, and chloroquine phosphate is effective. However, when it was used later, it was confirmed that the combination of Aifule with oseltamivir and Lianhua Qingwen was the same as that of Abidol and lopinavir and ritonavir. The regimen has no obvious effect, and the incidence of adverse reactions of oseltamivir and lopinavir and rit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of diammonium glycyrrhizinate
  • Novel application of diammonium glycyrrhizinate

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0041]Case 1: Wang Moumou, Guiyang, Guizhou, male, 79 years old, was hospitalized due to hemoptysis, and the test result was "interstitial pneumonia (sterile)", hospitalized for 8 days, no improvement, poor appetite, D-dimer Severely exceeded the standard, indicating diffuse blood coagulation throughout the body. Diammonium glycyrrhizinate capsules were used, 3 times a day, 3 capsules each time, and vitamin C 0.5g. Stop all other drugs for treatment. After taking the medicine for 3 days, the hemoptysis stopped, and the cough disappeared after a week. , The sticky phlegm in the throat disappeared, stopped taking diammonium glycyrrhizinate, and continued to take vitamin C. After three months, the routine supplement of vitamin C0.1g / day, the symptoms of chronic obstructive pulmonary disease were significantly relieved.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel application of diammonium glycyrrhizinate, and relates to the technical field of biological medicines. The invention relates to a novel application of diammonium glycyrrhizinate, in particular to a novel application of diammonium glycyrrhizinate in preparation of medicines for treating novel coronavirus pneumonia 2019-nCoV or chronic obstructive pulmonary disease, and meanwhile, diammonium glycyrrhizinate can also be used in combination with an immunopotentiator or a medicinal antioxidant. The diammonium glycyrrhizinate can replace hormones to resist inflammatory factors to protect the lung, but has no immunosuppressive effect and osteoporosis effect of the hormones.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the new application of diammonium glycyrrhizinate in the preparation and treatment of novel coronavirus pneumonia 2019-nCoV or chronic pulmonary obstruction. Background technique [0002] At present, for the treatment of the new type of coronavirus pneumonia 2019-nCoV, the initial clinical treatment plan adopted by the hospital is Ai Fu Le combined with oseltamivir and Lianhua Qingwen, and then successively announced arbidol and Lopi for the treatment of HIV Navir and ritonavir are effective, and chloroquine phosphate is effective. However, when it was used later, it was confirmed that the combination of Aifule with oseltamivir and Lianhua Qingwen was the same as that of Abidol and lopinavir and ritonavir. The regimen has no obvious effect, and the incidence of adverse reactions of oseltamivir and lopinavir-ritonavir is high, and chloroquine phosphate is only effective for mild ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K38/16A61K31/375A61P31/14A61P11/00
CPCA61K31/375A61K31/704A61K38/164A61P11/00A61P31/14A61K2300/00
Inventor 张涛涛
Owner GUIZHOU MAQIKA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap